Advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Friday backed Pfizer’s respiratory syncytial virus (RSV) vaccine for women in the middle of their third trimester of pregnancy to protect their babies from severe illness. The panel members by a vote of…

Read Full Article (External Site)